Introduction, disclosures

Overview of HIV Prevention  Brief primer on notable updates in HIV epidemiology  New infections: highest-incidence populations  Risk factors for HIV transmission  Effect of COVID‑19 on HIV transmission  HIV prevention options  Pre-exposure prophylaxis (PrEP)  Post-exposure prophylaxis  Risk-reducing behaviors  US Ending the HIV Epidemic strategy  PrEP coverage targets

Optimizing PrEP Delivery  Guideline recommendations  USPSTF  CDC  FDA-approved PrEP options: comparison of dosing route and frequency, efficacy and safety, patient-reported outcomes (e.g., satisfaction), and real-world data  Emtricitabine/tenofovir alafenamide  Emtricitabine/tenofovir disoproxil fumarate  Cabotegravir extended-release injectable suspension  PrEP prescribing: best practices  Identification of candidate patients  Selection of PrEP regimen through shared decision making  Monitoring and follow-up  Patient eduction and counseling  Increasing accessibility  Improving and monitoring adherence  Safety considerations for specific patient populations  Renal impairment  Pregnancy and breastfeeding  Hepatitis B or C coinfections  Looking to the future: advances in PrEP Islatravir  Lencapavir  Technology  Ingestible biosensors  Vaccination  Barriers to vaccine programs  Recent high-profile trial results  Ongoing clinical trials  Patient case(s)

Summary, conclusions, and best practices review

By the end of the session the participant will be able to:

• Discuss the US recommendations for the use of pre-exposure prophylaxis (PrEP) to meet national goals for HIV transmission.
• Analyze the data that support the safety and efficacy of PrEP for the prevention of HIV infection in various populations and apply it to patient cases.
• Describe efficacy, safety, and patient-reported outcomes data associated with novel and emerging long-acting PrEP options and other innovations in PrEP technology.
• Implement strategies for overcoming barriers to PrEP use, including adherence-related challenges.

ACCME Activity #202540668

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Connie Celum, MD, MPH, Professor of Global Health & Medicine, Director, Centerfor AIDS Research, University of Washington, has received financial compensation from Gilead and Merck for consulting work and Gilead for serving as an expert witness.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Gilead.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version